CLEVELAND, OHIO and SINGAPORE – February 01, 2016 – ImageIQ, an innovative Imaging Software and Contract Research Organization supporting preclinical research and clinical trials, announced today an agreement with InvitroCue (“IVQ”), a Singapore-based provider of biomedical quantitative image analytic products and services, to enhance and accelerate preclinical research through the use of cloud-based image analysis technology and to fuel business growth within the Asia market.

The distribution agreement will enhance IVQ’s product and service offerings in Asia through the utilization of ImageIQ’s assay-specific image analysis algorithm development and web-based image analysis software platform (ImageQuantity.com), both of which are imaging modality- and indication-agnostic. Using secure cloud technology, ImageQuantify.com provides validated automated image analysis software tools for common and custom imaging assays. As a result, any researcher has  access to  accurate, reproducible, objective imaging analytics that are affordable, readily accessible, and significantly reduce results turnaround times. The platform was developed and beta-tested with several international academics, medical device and pharmaceutical organizations. IQbots™, are validated image analysis algorithms for specific assays.  The IQbot Incubation Program will expand the IQbot catalog based upon market need and requests from researchers.

As a result, IVQ’s clients will have unique access to comprehensive imaging assay development, combined the objective and quantitative data produced by ImageIQ’s automated image processing technology.

“IVQ is delighted to strategically partner with ImagelQ,” said Dr. Steven Fang, InvitroCue Executive Director. “This is a validation of our deep domain marketing expertise and investments in transforming bio-analytics and imaging technologies in Asia. We are committed to usher in the changing technology paradigms and thereby deliver sustained value to our preclinical market by leveraging ImageIQ’s technology,” added Fang.

“This agreement is strategically important to us for our Asian market, and we are pleased to have IVQ as a partner,” said Tim Kulbago, ImageIQ CEO. “Their expertise in preclinical research perfectly aligns with ours in preclinical imaging and image analysis, and their experience and knowledge about the biomedical research market in Asia made it an ideal fit,” said Kulbago.

Dr. Shuoyu Xu, InvitroCue Technical Director added, “ImageIQ’s technology will join IVQ’s impressive CueFibrosis tool, which analyzes histological-pathology images to generate a quantitative fibrosis scoring index for a variety of liver-related research applications ranging from cirrhosis, fibrosis, Nonalcoholic Steatohepatitis and Hepatitis.

#   #  #

For more information, please contact:

 

ImageIQ, Inc.

Brett Hoover, VP Sales and Marketing

26801 Miles Road, Suite 103

Cleveland OH 44128

855-462-4347

bhoover@image-iq.com

http://www.image-iq.com

@ImageIQ

 

InvitroCue Limited

Yip Ai San, VP Corporate Development

11 Biopolis Way, Helios

#12-07/08

65-6460 0496

yas@invitrocue.com

https://invitrocue.com

@InvitroCue

 

About ImageIQ

 

ImageIQ is an Imaging Contract Research Organization (ICRO) that combines software engineering with biomedical and imaging expertise to provide quantitative visual analysis that enhances R&D and product efficacy/safety testing for research, medical device and pharmaceutical organizations. Incubated within Cleveland Clinic for the better part of a decade, ImageIQ provides customized image analytics and reporting, delivering objective quantitative evidence that speeds time to discovery and market entry, reduces internal overhead and improves grant proposal attractiveness and fundability.  By advancing the speed of research, ImageIQ customers can extend their expertise and abilities and complete work quickly, allowing innovative staff members to focus on creative solutions to research. www.Image-IQ.com

 

About InvitroCue

 

InvitroCue provides innovative products and services in the fields of in vitro DMPK, in vitro toxicology and digital pathology utilizing cell-based models and image analytics. InvitroCue’s technologies have been developed and validated together with leading pharmaceutical companies and scientific collaborators. The company uses in vitro technologies and assays to support better decision-making in preclinical drug studies and clinical research. Headquartered in Singapore and was spun out of Singapore, Agency for Science, Technology and Research (A*STAR), InvitroCue currently operates in Singapore and China. www.invitrocue.com

 

InvitroCue is listed on Australian Stock Exchange under ASX code “IVQ”.